Business Context and Reporting Period
This Form 8-K Current Report was filed by ARTELO BIOSCIENCES, INC. on March 5, 2026. The report details a material corporate action involving a reverse stock split of the Company's common stock, effective March 10, 2026.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on capital structure adjustments.
Material Changes
- Reverse Stock Split: The Company implemented a one-for-three (1-for-3) reverse stock split.
- Outstanding Shares: Reduced from 2,124,772 to approximately 708,258.
- Authorized Common Stock: Reduced from 500,000,000 to 166,666,667.
- Authorized Preferred Stock: Reduced from 69,444 to 23,148.
- Effective Date: The split became effective at 12:01 a.m. Eastern Time on March 10, 2026.
- New CUSIP: The new CUSIP number for the Common Stock is 04301G706.
Management Commentary and Unusual Items
Management stated the reverse split is intended to improve the marketability and liquidity of the Company's common stock. The Board of Directors effected this change without stockholder approval under Nevada Revised Statutes 78.207. No fractional shares will be issued; holders entitled to fractional shares will receive one whole share instead. All outstanding warrants and derivatives will automatically adjust to reflect the split.
Investor Verification Checklist
- Verify the new CUSIP number (04301G706) for trading purposes.
- Confirm the adjusted share count in brokerage accounts post-March 10, 2026.
- Review the terms of any outstanding warrants or derivatives to ensure proper adjustment.
- Check the press release (Exhibit 99.1) for additional details on the rationale and execution.